A Study to Investigate the Antitumor Activity, Safety, Tolerability, and Pharmacokinetics of BGB-A445 in Combination With Tislelizumab in Participants With Select Advanced Solid Tumors.

NCT05661955 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

113

Enrollment

INDUSTRY

Sponsor class

Conditions

Urothelial Carcinoma
Renal Cell Carcinoma
Melanoma
Non-mucosal Melanoma

Interventions

DRUG: BGB-A445
DRUG: Tislelizumab

Sponsor

BeiGene